1.  Garcia-Vallejo JJ, Koning N, Ambrosini M, Kalay H, Vuist I, Sarrami-Forooshani R, Geijtenbeek TB, van Kooyk Y.
    Glycodendrimers prevent HIV transmission via DC-SIGN on dendritic cells. Int Immunol. 2013. Jan 4. [Epub ahead of print]
  2. García-Vallejo JJ, Ambrosini M, Overbeek A, van Riel WE, Bloem K, Unger WW, Chiodo F, Bolscher JG, Nazmi K, Kalay H,  van Kooyk Y. Multivalent glycopeptides dendrimers for the targeted delivery of antigens to dendritic cells. Mol Immunol.  2013. 53(4):387-97.
  3. Van Kooyk Y, Unger WW, Fehres CM, Kalay H, García-Vallejo JJ.  Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation. Mol Immunol. 2012. S0161-5890.
  4.  Joshi MD, Unger WJ, Storm G, van Kooyk Y, Mastrobattista E. Targeting tumor antigens to dendritic cells using particulate carriers. J Control Release. 2012. 161(1):25-37.
  5. Unger WW, van Beelen AJ, Bruijns SC, Joshi M, Fehres CM, van Bloois L, Verstege MI, Ambrosini M, Kalay H, Nazmi K, Bolscher JG, Hooijberg E, de Gruijl TD, Storm G, van Kooyk Y.
    Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells. J Control Release. 2012. 160(1):88-95.
  6. Singh SK, Streng-Ouwehand I, Litjens M, Burgdorf S, Kurts C, Kalay H. Saeland E, Unger WWJ, and VAN KOOYK Y. Design of neo-glycoconjugates that target the Mannose Receptor and enhance TLR independent cross-presentation and Th1 polarization. Eur. J. Immunol, 41(4):916-25, 2011.
  7. Unger WW et al., DC-SIGN mediated antigen-targeting using glycan-modified liposomes: Formulation considerations. 2011. Int J Pharm. 416:426-32.
  8. Saeland E, Belo A.I., Mongera S., van Die I, Meijer GA and VAN KOOYK Y. Differential glycosylation of MUC1 and CEACAM5 between normal mucosa and tumour tissue of colon  cancer patients. Int. J. Cancer in press, 2011
  9. Unger WWK and VAN KOOYK Y.  ‘Dressed for success’ C-type  lectin receptors for the delivery of glycovaccines to dendritic  cells. Curr Opin Immunology, 23; 131-137, 2011.
  10. Saeland E. and VAN KOOYK Y. Highly glycosylated tumor antigens: interaction with the immune system. Biochem. Soc. Trans. 39:388-392, 2011.
  11. Singh, SK, Streng-Ouwehand I, Litjens M, Kalay H, Saeland E and VAN KOOYK Y. Tumour –associated glycan modifications of antigen enhance MGL2 dependent uptake and MHC class I restricted CD8 T cell responses. Int. J. Cancer, 2010.
  12. Singh SK, Stephani J, Schaefer M, Kalay H, Garcia-Vallejo JJ, den Haan J, Saeland E, Sparwasser T and VAN KOOYK Y.
    Targeting of glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.  Mol Immunol 47:164-174, 2009.
  13. VAN KOOYK, Y. and G. Rabinovich: Protein-glycan interactions  in the control of innate and adaptive immune responses. Nature  Immunol, 9(6):593-601, 2008.
  14. van Vliet, SJ, Saeland E, and VAN KOOYK, Y. Sweet preferences of MGL:carbohydrate specificity and function. Trends Immunol 29: 83-90, 2008.
  15. Aarnoudse CA, Bax M, Sanchez-Hernandez M, Garcia-Vallejo JJ and VAN KOOYK. Glycan modificatio of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells. Int. J. Cancer: 122, 839-846, 2008.
  16. Saeland E, van Vliet SJ, Bäckström M, van den Berg VC, Geijtenbeek  TB, Meijer GA, VAN KOOYK Y. The C-type lectin MGL expressed by dendritic cells detects glycan changes on MUC1 in colon carcinoma. Cancer Immunol Immunother.      56(8):1225-1236, 2007.
  17. van Vliet SJ, Gringhuis SI, Geijtenbeek TB and VAN KOOYK, Y. Regulation of effector T cells by antigen-presenting cells via interaction of the C-type lectin MGL with CD45. Nat. Immunol.  24:1200-1208, 2006.
  18. Aarnoudse CA, Vallejo JJ, Saeland E and VAN KOOYK, Y. Recognition of tumor glycans by antigen-presenting cells. Curr Opin Immunol 18:105-111, 2006.
  19. Geijtenbeek TBH, van Vliet SJ, Engering A, ’t Hart BA and VAN KOOYK, Y. Self- and non-self recognition by C-type lectins on Dendritic Cells. Ann. Rev. Immunol. 22:33-54, 2003
  20. TBH Geijtenbeek, R Torensma, SJ van Vliet, GCF van Duijnhoven, GJ Adema, VAN KOOYK Y and CG Figdor. Identification of DC-SIGN, a novel dendritic cell specific ICAM-3 receptor that supports primary immune responses. Cell 100: 575-585, 2000.
  21. TBH Geijtenbeek, DS Kwon, R Torensma, SJ van Vliet, GCF van Duijnhoven, J Middel, ILMHA Cornelissen, HSLM
    Nottet, VN Kewal Ramani, DR Littman, CG Figdor, and VAN KOOYK Y. DC-SIGN, a dendritic cell specific HIV-1 binding protein that enhances trans-infection of T cells, Cell 100: 587-597, 2000.